8-K: IN8bio Announces Strategic Shift: Pipeline Prioritization and Workforce Reduction

IN8bio is prioritizing its clinical pipeline, focusing on INB-100 for AML, and reducing its workforce by 49% to conserve cash.

Summary

• IN8bio is prioritizing its clinical pipeline, focusing on INB-100 for acute myeloid leukemia (AML) and suspending enrollment for INB-400 in glioblastoma (GBM).
• The company is reducing its workforce by 49%, from 37 to 19 full-time employees, across all functional areas and at both its New York City and Birmingham, Alabama sites.
• Executive management and the board have agreed to an 11% reduction in their cash compensation, effective September 1, 2024.
• The company expects to incur one-time costs of approximately $0.3 million related to the workforce reduction, primarily for severance payments.
• All affected employees will receive severance, continued health insurance, outplacement services, and full vesting of equity awards with an extended exercise period to September 4, 2027.
• IN8bio is also exploring strategic alternatives and partnership opportunities for its solid tumor program.
• The company had a Type B meeting with the FDA and received guidance on advancing INB-100 for AML as a post-transplant maintenance therapy.
• The INB-100 trial will continue to enroll patients in the expansion cohort, targeting approximately 25 patients, with completion expected in the first half of 2025.
• Long-term follow-up results for INB-100 are anticipated in late 2025 and 2026.
• As of August 30, 2024, 100% of AML patients remain relapse-free after receiving INB-100, with a median follow-up of 18.7 months.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The positive is the 100% progression-free survival in AML patients and the focus on the INB-100 program. The negative is the significant workforce reduction, suspension of the INB-400 trial, and the exploration of strategic alternatives, which suggests financial challenges. Overall, the sentiment is cautiously negative.

Positives

• The INB-100 program for AML has demonstrated a 100% progression-free survival rate as of August 30, 2024.
• The company is focusing resources on its most promising program, INB-100, which has received positive feedback from the FDA.
• The company is taking steps to preserve cash resources through workforce reductions and compensation cuts.
• Affected employees will receive severance packages, continued health insurance, outplacement services, and full vesting of equity awards.
• The company is exploring partnership opportunities for its solid tumor program, which could provide future value.

Negatives

• The company is implementing a significant workforce reduction of 49%, impacting a large portion of its employees.
• Enrollment in the Phase 2 clinical trial of INB-400 for GBM is being suspended.
• The company is incurring one-time costs of approximately $0.3 million related to the workforce reduction.
• The company is exploring strategic alternatives, which may indicate financial challenges.
• The company is reducing its spend and focusing on key milestones, which may indicate a need to conserve cash.

Risks

• The company may not be able to achieve the intended benefits of its DeltEx platform.
• There are risks to site initiation, clinical trial commencement, patient enrollment, and follow-up.
• The company may be unable to raise additional capital and could be forced to delay or terminate development programs.
• The outcomes of preclinical studies may not be predictive of clinical trial results.
• There are potential adverse effects arising from the testing or use of the company's product candidates.
• The company relies on third parties, including licensors and clinical research organizations.
• The company may not be able to find partnership opportunities for its solid tumor program.

Future Outlook

The company plans to focus on generating robust clinical data from INB-100, complete additional enrollment in the INB-100 trial by the first half of 2025, and explore partnership opportunities for its solid tumor program. Long-term follow-up results for INB-100 are anticipated in late 2025 and 2026.

Management Comments

• William Ho, Chief Executive Officer and co-founder, stated that the company is committed to building upon the data for INB-100 in AML.
• William Ho stated that the company is making the difficult decision to advance fewer pipeline programs, reduce spend, and focus on key milestones.
• William Ho expressed gratitude to all employees for their contributions towards the mission of Cancer Zero.

Industry Context

This announcement reflects a trend in the biotech industry where companies are prioritizing their most promising programs and reducing costs to extend their cash runway, especially in the current challenging funding environment. The focus on a single lead program and the exploration of partnerships are common strategies for companies in this sector.

Comparison to Industry Standards

• The 49% workforce reduction is significant and suggests a substantial restructuring, which is not uncommon for biotech companies facing financial pressures. For example, similar workforce reductions have been seen at companies like Agenus and Veru in recent times.
• The focus on a single lead program, INB-100, is a common strategy for companies with limited resources, similar to how companies like Celldex have focused on their lead candidate.
• The exploration of partnership opportunities for the solid tumor program is a typical approach for companies looking to monetize assets without further internal investment, similar to how companies like Adaptimmune have partnered on their programs.
• The 100% progression-free survival rate in AML patients is a very positive result, and if confirmed in a larger trial, would be considered a very strong result compared to industry standards for AML treatments.

Stakeholder Impact

• Shareholders may be concerned about the workforce reduction and the suspension of the INB-400 trial, but may be encouraged by the focus on INB-100.
• Employees are significantly impacted by the workforce reduction, with 49% of the workforce being laid off.
• Customers (patients) may be impacted by the changes in the clinical trial programs.
• Suppliers and creditors may be impacted by the company's cost-cutting measures.

Next Steps

• The company will continue to enroll patients in the INB-100 trial expansion cohort.
• The company will seek to add a control cohort to the INB-100 trial.
• The company will explore partnership opportunities for its solid tumor program.
• The company will monitor patients previously treated in the INB-200 and INB-400 clinical trials.
• The company will continue to work with the FDA on the development of INB-100.

Key Dates

Keywords

IN8bio, INB-100, AML, Acute Myeloid Leukemia, Gamma-delta T cell therapy, Workforce reduction, Clinical trial, Pipeline prioritization, GBM, Glioblastoma, Severance, FDA, Strategic alternatives, Haplotransplantation